Chronic hepatitis B or C is easily recurrent and prolonged, and can lead to cirrhosis and hepatocellular carcinoma, so proper antiviral therapy is the fundamental treatment. To date, subcutaneous injection of long-acting alpha-interferon is one of the most effective treatment methods. Interferon can not only directly inhibit the replication of hepatitis B or C virus, but also stimulate the body’s immunity against hepatitis B virus and produce antiviral effects. Shanghai Shuguang Hospital East Hospital liver disease department Yang Wanfeng interferon treatment during and after the end of treatment should follow the doctor’s instructions to follow up on time, because: 1, interferon has certain side effects. Common in adults: fever, fatigue, sleepiness, muscle pain, flu-like symptoms, hair loss, and in severe cases, bone marrow suppression, manifested as peripheral leukopenia, thrombocytopenia, etc. The purpose of the scheduled follow-up is to detect these possible side effects and make appropriate treatment in time.
2. Even if the same patient has chronic hepatitis B or C, the specific condition varies from patient to patient, and the treatment plan must often be individualized to obtain the best results. This requires specific adjustments to be made for each patient during treatment. A follow-up visit allows the doctor to understand the patient’s specific situation as early as possible so that he or she can make the necessary treatment adjustments for the patient in a timely manner.
3, limited to the differences in the state of immune function of each patient’s body, so after the end of treatment to achieve the expected effect of patients will inevitably be part of the patients after the end of treatment in different periods of relapse. However, if relapse can be detected in time, treatment can be done on the basis of the previous efficacy, and better results can still be obtained.
If a patient with hepatitis C is intolerant to ribavirin, monotherapy with this product can be continued.
When this product is used in combination with ribavirin, please refer to the instructions for dose adjustment in case of adverse reactions to ribavirin. Patients with chronic hepatitis often experience fluctuations in liver function. As with other a-interferons, ALT elevations can occur with treatment with this product, including in patients with improved viral response. A dose reduction to 135 μg should be considered when patients with hepatitis C develop persistent ALT elevations. discontinuation should be considered if ALT remains persistently elevated after dose reduction, or if elevated bilirubin or hepatic dysfunction occurs. A transient ALT rebound is commonly seen in patients with chronic hepatitis B. The rebound value often exceeds ten times the upper limit of normal. The presence of rebound suggests that immune clearance (seroconversion) has occurred. Increasing the frequency of liver function monitoring should be considered when continuing treatment during ALT rebound. If the dose of this product is reduced or treatment is temporarily discontinued, regular therapy can be resumed when ALT returns to normal.
No dose adjustment is required for patients with creatinine clearance greater than 20 ml/min. However, when this product is used in combination with ribavirin, the instructions for ribavirin should be carefully consulted. In patients with end-stage renal function on hemodialysis, where clearance is reduced by 25-45%, exposure at a dose of 135 μg is similar to that at a dose of 180 μg in patients with normal renal function. It is recommended that caution be exercised when this product is used in these patients, that it should be closely monitored, and that the dose of this product should be reduced in the event of adverse reactions.
Follow-up observation after the end of treatment: Long-term follow-up is required after discontinuation of the drug. Within 1 year after the end of treatment, liver function, hepatitis B two-to-one, and HBV-DNA quantification should be rechecked every 3 months in order to detect and manage the relapse of the disease in a timely manner. After stabilization of the disease, liver function, hepatitis B and HBV-DNA quantification can be rechecked every six months.
If there is any other discomfort, please come to our hospital in time. You are welcome to keep in touch with us frequently. As well as enabling us to answer your questions and provide other necessary help and consultation.